ClinicalTrials.Veeva

Menu

Inflammatory Markers in Sputum After LPS Inhalation

C

Centre Hospitalier Universitaire Brugmann

Status

Unknown

Conditions

Inflammation

Treatments

Biological: LPS

Study type

Interventional

Funder types

Other

Identifiers

NCT01081392
CIA-01.2

Details and patient eligibility

About

The purpose of the study is to measure inflammatory biomarkers in sputum and peripheral blood in healthy volunteers after inhalation of single doses of LPS (20 mcg) administered as particles of different sizes.

Full description

Endotoxins are inflammatory substances present in the environment. In man, the inhalation of the lipopolysaccharride moiety (LPS) induces measurable immune responses. With an inhaled single dose of 20 micron, the inflammatory response in man is sub-clinical. During bronchoprovocation tests with allergens, the particle size determines to a large extent the intensity of the response. the response to LPS as a function of particle size is not known and will be studied in this study.

Enrollment

12 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy volunteer, non-smoking or ex-smoker >1mth and <10packs/year
  • normal ECG
  • normal lab values for hematology, ionogram, AST, ALT, alk phosphatases, urea, creatinine and CRP
  • FEV1/forced vital capacity >0.7 and FEV1>80% of predicted value
  • able to produce valid sputum following induction (>=50% viable cells, <50% squamous cells and <60% neutrophils)
  • females must be using contraception
  • written informed consent

Exclusion criteria

  • infection within 14 days
  • history of bronchial asthma
  • obstructive respiratory condition with FEV1 <70% of theoretical value

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

12 participants in 6 patient groups

LPS sequence 1
Experimental group
Description:
Nebulizers A then B then C
Treatment:
Biological: LPS
LPS sequence 2
Experimental group
Description:
Nebulizers B then C then A
Treatment:
Biological: LPS
LPS sequence 3
Experimental group
Description:
Nebulizers C then A then B
Treatment:
Biological: LPS
LPS sequence 4
Experimental group
Description:
Nebulizers A then C then B
Treatment:
Biological: LPS
LPS sequence 5
Experimental group
Description:
Nebulizers C then B then A
Treatment:
Biological: LPS
LPS sequence 6
Experimental group
Description:
Nebulizers B then A then C
Treatment:
Biological: LPS

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems